Description: Hemostemix Inc is a Canada-based clinical-stage biotechnology company. The Company's principal business is to develop, manufacture and commercialize blood-derived cell therapies for medical conditions, including critical limb ischemia (CLI). The Company's clinical-stage candidate, ACP-01, is an autologous cell therapy for the treatment of CLI. ACP-01 is in a Phase II clinical trial in Canada, South Africa and the United States. The Company also focuses on developing other cell products, such as bone cell precursors (BCPs), myocardial cell precursors (MCPs) and neural cell precursors (NCPs). It operates in Canada and Israel. The Company has approximately 2,200 square foot research and manufacturing facility in Ness Ziona, Israel. Hemostemix Limited is the subsidiary of the Company.
Home Page: www.hemostemix.com
HEM Technical Analysis
707-7th Avenue SW
Calgary,
AB
T2P 3H6
Canada
Phone:
403-506-3373
Officers
| Name | Title |
|---|---|
| Mr. Thomas A. Smeenk B.A., BA Hons | Co-Founder, Pres, CEO & Director |
| Ms. Christina Wu CPA | Interim Chief Financial Officer |
| Cameron Cole | Head of Investor Relations |
| Dr. Fraser C. Henderson Sr., M.D. | Chief Medical Officer |
| Mr. Thomas Abraham C.A. | Pres of PreCerv Inc. |
Exchange: V
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 27.7582 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |